21.2 C
New York
Monday, May 27, 2024

XTL Biopharma Buys Stake in Proteologics from Teva

Courtesy of Benzinga.

XTL Biopharmaceuticals Ltd. announced on November 21^st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium). The Shares represent all of Teva’s shares in Proteologics and represent approximately 31.35% of Proteologics issued and outstanding share capital.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,159FansLike
396,312FollowersFollow
2,300SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x